Title: Ixazomib: an oral proteasome inhibitor for the treatment of multiple myeloma
Abstract: Introduction: Over the past decade, the introduction of proteasome inhibitors (PIs) and immunomodulatory agents (IMiDs) has dramatically improved the progression-free and overall survival of patients with multiple myeloma (MM). Ixazomib, a second-generation oral reversible 20S PI, is one of the first oral PIs in development for patients with MM.
Publication Year: 2015
Publication Date: 2015-12-09
Language: en
Type: article
Indexed In: ['crossref']
Access and Citation
Cited By Count: 3
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot